Johnson & Johnson (NYSE:JNJ) Receives Outperform Rating from Royal Bank Of Canada

Royal Bank Of Canada reaffirmed their outperform rating on shares of Johnson & Johnson (NYSE:JNJ) in a report issued on Monday,Benzinga reports. Royal Bank Of Canada currently has a $255.00 price target on the stock.

JNJ has been the subject of a number of other research reports. JPMorgan Chase & Co. lifted their price objective on Johnson & Johnson from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Thursday, March 5th. TD Cowen raised their target price on Johnson & Johnson from $222.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Wall Street Zen downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Daiwa Securities Group raised their price objective on shares of Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a research note on Thursday, January 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Stock Up 0.7%

JNJ stock opened at $242.22 on Monday. The company has a market capitalization of $583.40 billion, a P/E ratio of 21.92, a price-to-earnings-growth ratio of 2.37 and a beta of 0.34. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $251.71. The firm’s fifty day simple moving average is $237.87 and its 200-day simple moving average is $211.39. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The firm had revenue of $24.28 billion during the quarter. As a group, equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s payout ratio is currently 47.06%.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total value of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 22,623 shares of the stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59. Following the transaction, the executive vice president directly owned 26,769 shares of the company’s stock, valued at $6,540,469.77. The trade was a 45.80% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 30,142 shares of company stock valued at $7,360,528. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

Several large investors have recently made changes to their positions in JNJ. Blueline Advisors LLC acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $25,000. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson during the third quarter worth about $26,000. Cresta Advisors Ltd. purchased a new stake in Johnson & Johnson during the 4th quarter valued at about $26,000. Evolution Wealth Management Inc. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at about $27,000. Finally, Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at about $28,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.